Researchers from Tokyo Metropolitan University have identified how proteins collect abnormally in neurons, a feature of neurodegenerative diseases like Alzheimer’s.
Zynteglo and Skysona combine for 16 patient starts since approvals last year
Bluebird bio’s gene therapy Zynteglo, which was approved by the FDA to treat patients with transfusion-dependent thalassemia last August, hasn’t had many takers. Bluebird said
August 9, 2023